ACTUATE THERAPEUTICS INC

ACTU is the stock ticker symbol for Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company. The company focuses on developing therapies for patients with cancer and inflammatory diseases. Its lead drug candidate, elraglusib, targets glycogen synthase kinase-3 beta (GSK-3β). ACTU stock represents an ownership stake in this company and trades on a U.S. exchange. Investors can find the latest price and company details on the stock page.

ACTU stock is listed on the Nasdaq Capital Market under the ticker symbol ACTU. The Nasdaq is a major U.S. electronic exchange where many biotech and growth companies are traded. Investors can buy or sell shares through a brokerage account that offers access to Nasdaq-listed securities. For the most current listing information, refer to the latest data displayed on this page.

Recent performance of ACTU stock can be seen in the price chart and performance metrics on this page. As a clinical-stage biotech, the stock may react to news about clinical trials, regulatory updates, or financial results. For the latest price changes, including daily and year-to-date performance, please check the current data shown on the page.

Before researching ACTU, note that it is a clinical-stage biopharmaceutical company, meaning it may have no approved products and could be years away from generating product revenue. Its financials often reflect research and development expenses rather than sales. The stock can be volatile and sensitive to clinical trial outcomes. Reviewing SEC filings, pipeline updates, and cash position can provide context. Always check the latest ACTU data on this page for current information.

For a clinical-stage biotech like ACTU, key financial metrics include cash and cash equivalents, research and development expenses, general and administrative costs, and net loss. Investors often monitor the cash runway, which indicates how long the company can fund operations without additional financing. Other useful metrics include operating expenses, shares outstanding, and any collaboration revenue. These figures are reported in quarterly and annual financial statements, which can be found in SEC filings or on the company's investor relations site.

ACTU faces risks typical of clinical-stage biopharmaceuticals, including the possibility that its drug candidates fail in clinical trials or do not receive regulatory approval. The company may need to raise additional capital, which could dilute existing shareholders. It operates in a highly competitive industry with significant regulatory and scientific hurdles. Market conditions and investor sentiment toward biotech can also affect the stock. For a full risk assessment, review the risk factors in ACTU's SEC filings.